-
Advances in fundamental oncology: the year 2020 update
DOI 10.31917/2201001
E.N. Imyanitov
-
New and promising immune oncology drugs combinations
DOI 10.31917/2201022
N.М. Volkov
-
Combinations of immunotherapy and other drugs
DOI 10.31917/2201033
V.A. Chubenko
-
Tumour board for decision making
DOI 10.31917/2103145
V.A. Chubenko
-
Urgent situations in oncology
DOI 10.31917/2103188
F.V. Moiseenko
-
Myeloid-derived suppressor cells: origin, phenotype, functions, mechanisms of interaction with immune cells during tumor growth
DOI 10.31917/2103249
T.N. Zabotina, I.O. Panchuk, D.V. Tabakov, E.N. Zakharova
-
Nutritive detoxification support in ent oncology
DOI 10.31917/2103262
N.A. Daihes, T.L. Pilat, V.V. Vinogradov, S.S. Reshulsky, E.B. Fedorova, R.A. Khanferyan
-
Pending issues of standard approaches in oncology
DOI 10.31917/2102081
A.A. Tryakin, M.Yu. Fedyanin, I.A. Pokataev, A.V. Petrovsky
-
Urgent issues of drug therapy and possible solutions
DOI 10.31917/2102106
E.V. Karabina
-
Vaccination against hpv is the most effective of the known methods of primary prevention of malignant tumors
DOI 10.31917/2102123
D.G. Zaridze, A.F. Mukeria, I.S. Stilidi
-
Advances in fundamental oncology: Year 2019 update
DOI 10.31917/2101001
E.N. Imyanitov
-
Microbiome and its role in oncology
DOI 10.31917/2101011
F.V. Moiseenko, S.V. Ugai, N.M. Volkov
-
What has changed in clinical oncology practice In 2019?
DOI 10.31917/2101021
M.Y. Fedyanin
-
First line dosointensive chemotherapy for Disseminated ovarian cancer after non optimal Cyted reduction: Results of the phase ii study
DOI 10.31917/2101037
A.A. Rumyantsev, A.S. Tyulyandina, I.A. Pokataev, K.Yu. Morkhov, V.M. Nechushkina, V.E. Nikulin, S.O. Nikogosyan, K.I. Zhordania, S.A. Tyulyandin
-
Clinical experience of afatinib application In non-cell lung cancer of lung. Ii line of therapy
DOI 10.31917/2101064
L.M. Kogoniya, E.V. Markarova, G.A. Stashuk, V.E. Shikina
-
Long-lasting full remission after selective intra-arterial chemotherapy for recurrence of locally advanced oral mucosa carcinoma
DOI 10.31917/2004336
I.P. Moshurov, A.N. Redkin, N.A. Znatkova, M.S. Olshansky, A.Yu. Shklyarov, A.V. Tsurikova, S.A. Stikina
-
Dynamics of pathological factors after «test» course of preoperative endocrine therapy in menopausal patients with earlyer positive breast cancer and its effect on survival
DOI 10.31917/2004326
M.A. Frolova, M.B.Stenina, Y.I. Kochetkova, A.V. Petrovsky, O.V. Krohina, Y.V. Vishnevskaya, S.A. Tyulyandin
-
Hormone replacement therapy in patients with a history of cancer
DOI 10.31917/2004310
N.E. Levchenko, E.A. Efremov, E.V. Kasatonova, Yu.S. Sidorenko, Y.I. Melnik, A.V. Koryakin
-
Intraperitoneal chemotherapy in patients with advanced ovarian cancer: phase 2 institutional study
DOI 10.31917/2004299
A.S. Tyulyandina, V.М. Nechushkina, L.V. Cherkes, K.Y. Morkhov, A.A. Rumyantsev, I.A. Pokataev, E.V. Glazkova, E.R. Virshke, D.Y. Frantsev, K.I. Zhordania, Y.V. Bujdenok, R.K. Valiev, A.V. Petrovsky, Y.S. Sergeev, I.V. Panichenko, A.A. Bulanov, M.B. Stenina, S.A. Tyulyandin
-
Metronomic chemotherapy: efficacy in real clinical practice
DOI 10.31917/2004289
V.A. Chubenko, L.A. Zagorskaya, V.S. Chubenko, F.V. Moiseenko, N.Kh. Abduloeva, A.S. Zhabina, M.M. Kramchaninov, K.V. Shelekhova, A.A. Meldo, E.M. Zykov, A.A. Kudryavcev, E.V. Napolskaya, V.M. Moiseyenko